Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Prevalence and Risk of Severe Cognitive Impairment in Advanced Chronic Kidney Disease
Burns, Christine , Tupper, David E., Davey, Cynthia , Slinin, Yelena , Lakshminarayan, Kamakshi , Rossom, Rebecca C. , Pederson, Sarah, Gilbertson, David T. , Murray, Anne M. , Knopman, David S.

Mayo Clinic

The Journals of Gerontology: Series A | December 13, 2017 | Volume: 73 | Issue: 3 | Pages: 393-399

10.1093/gerona/glx241 | PMID 29244090 Get It

Management of Adolescent–Parent Dyads’ Discordance for Willingness to Participate in a Reproductive Health Clinical Trial
Francis, Jenny , Fraiz, Lauren Dapena, Roche, Ariel M. de, Catallozzi, Marina , Breitkopf, Carmen Radecki , Rosenthal, Susan L. , Francis, Jenny K R , Radecki Breitkopf, Carmen, Roche, Ariel M. de

Mayo Clinic

Journal of Empirical Research on Human Research Ethics | December 11, 2017 | Volume: 13 | Issue: 1 | Pages: 42-49

10.1177/1556264617745409 | PMID 29226745 Get It

The objective of this study is to understand the resolution of discordance between adolescent–parent dyads about participation in research. Adolescent (14-17 years) and parent dyads were recruited from NYC pediatric clinics to assess attitudes toward research participation. A subset of dyads participated in videotaped discussions about participation in a hypothetical study. Videos from dyads that held strongly discordant opinions about participation ( n = 30) were content-coded and analyzed using a thematic framework approach. Strategies used to resolve discordance included asserting authority, granting autonomy, or recognizing inaccurate assumptions using a variety of communication behaviors. Missed opportunities to enroll initially discordant dyads may be avoided by allowing time for adolescents and parents to elicit information, clarify a situation, or convince the other.
Giant Cell Tumor of Bone in Patients 55 Years and Older
Broehm, Cory , Inwards, Carrie Y., Al‐Ibraheemi, Alyaa , Wenger, Doris E. , Jenkins, Sarah M. , Jin, Long , Oliveira, André M. , Zreik, Riyam , Carter, Jodi M. , Boland, Jennifer M. , Fritchie, Karen , Broehm, Cory J, Fritchie, Karen J. , Carter, Jodi

Mayo Clinic

American Journal of Clinical Pathology | December 6, 2017 | Volume: 149 | Issue: 3 | Pages: 222-233

10.1093/ajcp/aqx155 | PMID 29425276 Get It

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Norquist, Barbara M. , Brady, Mark F. , Harrell, Maria I., Lee, Ming K. , Bernards, Sarah S., Casadei, Silvia , Burger, Robert A. , Tewari, Krishnansu S. , Mannel, Robert S., Bailey, Cheryl L., Rubin, Stephen C. , Soper, John T. , Lankes, Heather A. , Ramirez, Nilsa C. , King, Mary‐Claire , Birrer, Michael J. , Swisher, Elizabeth M. , Glaser, Gretchen , Swisher, Elizabeth M , Walsh, Tom D. , Gülsüner, Süleyman , Backes, Floor , Norquist, Barbara

Mayo Clinic

Clinical Cancer Research | November 30, 2017 | Volume: 24 | Issue: 4 | Pages: 777-783

10.1158/1078-0432.ccr-17-1327 | PMID 29191972 Get It

Abstract Purpose: We hypothesized that mutations in homologous recombination repair (HRR) genes beyond BRCA1 and BRCA2 improve outcomes for ovarian carcinoma patients treated with platinum therapy and would impact the relative benefit of adding prolonged bevacizumab. Experimental Design: We sequenced DNA from blood and/or neoplasm from 1,195 women enrolled in GOG-0218, a randomized phase III trial in advanced ovarian carcinoma of bevacizumab added to carboplatin and paclitaxel. Defects in HRR were defined as damaging mutations in 16 genes. Proportional hazards models were used to estimate relative hazards for progression-free survival (PFS) and overall survival (OS). Results: Of 1,195 women with ovarian carcinoma, HRR mutations were identified in 307 (25.7%). Adjusted hazards for progression and death compared with those without mutations were lower for women with non-BRCA HRR mutations [HR = 0.73; 95% confidence interval (CI), 0.57–0.94; P = 0.01 for PFS; HR = 0.67; 95% CI, 0.50–0.90; P = 0.007 for OS] and BRCA1 mutations (HR = 0.80; 95% CI, 0.66–0.97; P = 0.02 for PFS; HR = 0.74; 95% CI, 0.59–0.94; P = 0.01 for OS) and were lowest for BRCA2 mutations (HR = 0.52; 95% CI, 0.40–0.67; P < 0.0001 for PFS; HR = 0.36; 95% CI, 0.25–0.53; P < 0.0001 for OS). A test of interaction showed no difference in the effect of bevacizumab on PFS between cases with and without mutations. Conclusions: HRR mutations, including non-BRCA genes, significantly prolong PFS and OS in ovarian carcinoma and should be stratified for in clinical trials. The benefit of adding bevacizumab was not significantly modified by mutation status. Clin Cancer Res; 24(4); 777–83. ©2017 AACR.
International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)
O’Mahony, Constantinos , Jichi, Fatima, Ommen, Steve R. , Christiaans, Imke , Arbustini, Eloisa , García‐Pavía, Pablo , Olivotto, Iacopo , Kitaoka, Hiroaki , Gotsman, Israel , Carr‐White, Gerald, Mogensen, Jens , Antoniades, Loizos , Tang, Hak Chiaw , Geske, Jeffrey B. , Siontis, Konstantinos C. , Mahmoud, Karim D. , Vermeer, Alexa M.C. , Wilde, Arthur A.M. , Favalli, Valentina , Guttmann, Oliver , Gallego‐Delgado, María , Domínguez, Fernándo , Tanini, Ilaria , Kubo, Toru , Keren, Andre , Bueser, Teofila , Waters, Sarah, Issa, Issa Farah , Malcolmson, James , Burns, Tom, Sekhri, Neha, Hoeger, Christopher W. , Omar, Rumana , Elliott, Perry , Olivotto, Iacopo , Garcia-Pavia, Pablo , Geske, Jeffrey B , Cecchi, Franco , Mohiddin, Saidi , Maurer, Matthew J. , Dominguez, Fernando

Mayo Clinic

Circulation | November 30, 2017 | Volume: 137 | Issue: 10 | Pages: 1015-1023

10.1161/circulationaha.117.030437 | PMID 29191938 Get It

Background: Identification of people with hypertrophic cardiomyopathy (HCM) who are at risk of sudden cardiac death (SCD) and require a prophylactic implantable cardioverter defibrillator is challenging. In 2014, the European Society of Cardiology proposed a new risk stratification method based on a risk prediction model (HCM Risk-SCD) that estimates the 5-year risk of SCD. The aim was to externally validate the 2014 European Society of Cardiology recommendations in a geographically diverse cohort of patients recruited from the United States, Europe, the Middle East, and Asia. Methods: This was an observational, retrospective, longitudinal cohort study. Results: The cohort consisted of 3703 patients. Seventy three (2%) patients reached the SCD end point within 5 years of follow-up (5-year incidence, 2.4% [95% confidence interval {CI}, 1.9–3.0]). The validation study revealed a calibration slope of 1.02 (95% CI, 0.93–1.12), C-index of 0.70 (95% CI, 0.68–0.72), and D-statistic of 1.17 (95% CI, 1.05–1.29). In a complete case analysis (n= 2147; 44 SCD end points at 5 years), patients with a predicted 5-year risk of <4% (n=1524; 71%) had an observed 5-year SCD incidence of 1.4% (95% CI, 0.8–2.2); patients with a predicted risk of ≥6% (n=297; 14%) had an observed SCD incidence of 8.9% (95% CI, 5.96–13.1) at 5 years. For every 13 (297/23) implantable cardioverter defibrillator implantations in patients with an estimated 5-year SCD risk ≥6%, 1 patient can potentially be saved from SCD. Conclusions: This study confirms that the HCM Risk-SCD model provides accurate prognostic information that can be used to target implantable cardioverter defibrillator therapy in patients at the highest risk of SCD.
Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands’ Susceptibility Gene Mutation Status
Antwi, Samuel O. , Fagan, Sarah , Chaffee, Kari G. , Hu, Chunling , Lilyquist, Jenna , Oberg, Ann L. , Petersen, Gloria M. , Rabe, Kari G. , Polley, Eric C. , Hart, Steven N. , Shimelis, Hermela , Gnanaolivu, Rohan D., McWilliams, Robert R. , Antwi, Samuel O , Hu, Chunling , Bamlet, William R. , Gnanaolivu, Rohan , Couch, Fergus J.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 27, 2017 | Volume: 111 | Issue: 3 | Pages: 264-271

10.1093/jnci/djx272 | PMID 29982661 Get It

Calibrated Peer Review for Interpreting Linear Regression Parameters: Results from a Graduate Course
Enders, Felicity B., Jenkins, Sarah M. , Hoverman, Verna, Enders, Felicity B., Hoverman, Verna R.

Mayo Clinic

Journal of Statistics Education | November 24, 2017 | Volume: 18 | Issue: 2 | Pages: 50

10.1080/10691898.2010.11889489 Get It

Factors Associated With Failure of Adult Strabismus–20 Questionnaire Scores to Improve Following Strabismus Surgery
Leske, David A. , Philbrick, Kemuel L. , Holmes, Jonathan M. , Hatt, Sarah R. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | November 22, 2017 | Volume: 136 | Issue: 1 | Pages: 46

10.1001/jamaophthalmol.2017.5088 | PMID 29167898 Get It

Syringe lubricant and adverse reactions
Wambier, Carlos Gustavo , Ostroski, Tayza Katelline Danilau , Wambier, Sarah Perillo de Farias , Beltrame, Flávio Luís , Cappel, Mark A., Piñeiro‐Maceira, Juan , Wambier, Carlos G , Cappel, Mark A.

Mayo Clinic

International Journal of Dermatology | November 20, 2017 | Volume: 57 | Issue: 1 | Pages: 122-123

10.1111/ijd.13825 | PMID 29152724 Get It

Prevalence and Associations of Central-Peripheral Rivalry–Type Diplopia in Patients With Epiretinal Membrane
Veverka, Kevin K. , Leske, David A. , Brown, William L. , Iezzi, Raymond , Holmes, Jonathan M. , Barkmeier, Andrew J. , Lezzi, Raymond, Hatt, Sarah R. , Brown, William L., Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | November 16, 2017 | Volume: 135 | Issue: 12 | Pages: 1303

10.1001/jamaophthalmol.2017.4350 | PMID 29145554 Get It